OncoCyte Corporation (OCX): Price and Financial Metrics
OCX Price/Volume Stats
Current price | $3.02 | 52-week high | $7.40 |
Prev. close | $2.98 | 52-week low | $2.08 |
Day low | $2.94 | Volume | 9,900 |
Day high | $3.07 | Avg. volume | 11,838 |
50-day MA | $3.08 | Dividend yield | N/A |
200-day MA | $3.41 | Market Cap | 24.95M |
OCX Stock Price Chart Interactive Chart >
OCX Stock Summary
- Of note is the ratio of ONCOCYTE CORP's sales and general administrative expense to its total operating expenses; 99.9% of US stocks have a lower such ratio.
- As for revenue growth, note that OCX's revenue has grown -129.16% over the past 12 months; that beats the revenue growth of merely 0.45% of US companies in our set.
- In terms of volatility of its share price, OCX is more volatile than 96.7% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to ONCOCYTE CORP, a group of peers worth examining would be NC, SAIC, NVR, FTK, and PCH.
- Visit OCX's SEC page to see the company's official filings. To visit the company's web site, go to www.oncocyte.com.
OCX Valuation Summary
- OCX's price/sales ratio is -8.8; this is 309.52% lower than that of the median Healthcare stock.
- OCX's price/sales ratio has moved NA NA over the prior 97 months.
Below are key valuation metrics over time for OCX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
OCX | 2023-12-29 | -8.8 | 0.6 | -0.4 | -0.1 |
OCX | 2023-12-28 | -8.8 | 0.6 | -0.4 | -0.1 |
OCX | 2023-12-27 | -8.8 | 0.6 | -0.4 | -0.1 |
OCX | 2023-12-26 | -8.9 | 0.6 | -0.4 | -0.1 |
OCX | 2023-12-22 | -9.1 | 0.6 | -0.4 | -0.2 |
OCX | 2023-12-21 | -10.0 | 0.6 | -0.4 | -0.2 |
OCX Growth Metrics
- Its 2 year price growth rate is now at -59.63%.
- The 3 year net income to common stockholders growth rate now stands at -344.88%.
- Its year over year cash and equivalents growth rate is now at -62.46%.
The table below shows OCX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 8.097 | -42.985 | -64.031 |
2022-06-30 | 8.064 | -42.583 | -68.276 |
2022-03-31 | 8.027 | -39.373 | -70.469 |
2021-12-31 | 7.727 | -35.941 | -64.097 |
2021-09-30 | 4.641 | -35.026 | -34.521 |
2021-06-30 | 4.212 | -30.032 | -27.504 |
OCX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- OCX has a Quality Grade of F, ranking ahead of 0.09% of graded US stocks.
- OCX's asset turnover comes in at 0.04 -- ranking 335th of 681 Pharmaceutical Products stocks.
- ITCI, BHVN, and LFVN are the stocks whose asset turnover ratios are most correlated with OCX.
The table below shows OCX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.040 | -0.136 | -2.643 |
2021-03-31 | 0.030 | -0.173 | -1.674 |
2020-12-31 | 0.021 | -0.525 | -1.429 |
2020-09-30 | 0.013 | -0.595 | -1.555 |
2020-06-30 | 0.003 | -2.384 | -1.709 |
2020-03-31 | 0.000 | -9.812 | -2.256 |
OCX Price Target
For more insight on analysts targets of OCX, see our OCX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $8.67 | Average Broker Recommendation | 1.4 (Strong Buy) |
OncoCyte Corporation (OCX) Company Bio
OncoCyte Corporation focuses on developing diagnostic tests for the detection of breast, bladder, and lung cancers. The company was founded in 2009 and is based in Alameda, California.
Latest OCX News From Around the Web
Below are the latest news stories about ONCOCYTE CORP that investors may wish to consider to help them evaluate OCX as an investment opportunity.
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays- Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests (LDTs) to seek regulatory approval. This move positions Oncocyte wi |
OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the HorizonStrategic Focus on Upcoming Product Launches Amidst Tightened Cash Burn Management |
Oncocyte Reports Third Quarter 2023 Financial Results-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial re |
Oncocyte to Announce Third Quarter 2023 Financial ResultsConference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ETIRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issu |
Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months EarlierOncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference. |
OCX Price Returns
1-mo | 0.67% |
3-mo | 5.59% |
6-mo | -6.79% |
1-year | -43.47% |
3-year | -96.86% |
5-year | -95.93% |
YTD | 20.80% |
2023 | -61.05% |
2022 | -85.21% |
2021 | -9.21% |
2020 | 6.22% |
2019 | 63.04% |
Loading social stream, please wait...